Medicine and Dentistry
Neoplasm
100%
Endoscopy
59%
Barrett Esophagus
55%
Bevacizumab
53%
Radioactive Tracer
43%
Surgery
30%
Molecular Imaging
29%
Esophageal Adenocarcinoma
22%
Dysplasia
22%
Vasculotropin
21%
Endoscopic Surgery
18%
Ex Vivo
17%
Malignant Neoplasm
16%
Positron Emission Tomography
15%
Positron Emission Tomography
15%
Esophageal Cancer
14%
Oncology
14%
Surgical Margin
13%
Vasculotropin A
13%
Adenoma
12%
Cetuximab
11%
Adverse Event
11%
Specific Tumor
10%
Lymph Node Metastasis
10%
Biopsy
9%
Inflammatory Bowel Disease
9%
Epidermal Growth Factor Receptor
9%
Colorectal Cancer
9%
Disease
9%
Biological Marker
9%
Optical Imaging
9%
Metastatic Carcinoma
8%
Epidermal Growth Factor Receptor 2
8%
Recurrent Disease
8%
Cancer Therapy
8%
Positron Emission Tomography-Computed Tomography
8%
Colonoscopy
7%
Functional Genomics
7%
Gamma Urogastrone
7%
Clinical Trial
7%
Randomized Controlled Trial
7%
Endoscopic Ultrasound
7%
Chemoradiotherapy
6%
Breast Cancer
6%
Colorectal Adenoma
6%
Radiofrequency Ablation
6%
Meta-Analysis
6%
Sensitivity and Specificity
6%
Single-Photon Emission Computed Tomography
6%
Endoscopic Submucosal Dissection
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
47%
Bevacizumab
38%
Tracer
34%
Vasculotropin
16%
Malignant Neoplasm
16%
Esophageal Adenocarcinoma
14%
Barrett Esophagus
13%
Esophagus Cancer
11%
Biological Marker
10%
Cetuximab
10%
Trastuzumab
8%
Disease
7%
Melanoma
6%
Antiangiogenic
6%
Luminespib
6%
Inflammatory Bowel Disease
6%
Adenoma
6%
Meningioma
6%
Biodistribution
5%
Mouse
5%
Vedolizumab
5%
Lymph Node Metastasis
5%
Indium 111
5%
Monoclonal Antibody
5%
Receptor
5%
Drug Distribution
5%
Epidermal Growth Factor Receptor 2
5%
Keyphrases
Barrett's Esophagus
22%
Esophageal Adenocarcinoma
15%
Fluorescence Endoscopy
9%
Esophageal Cancer
9%
Barrett's Neoplasia
7%
Expert Center
6%
Submucosal
6%
Community Hospital
6%
Endoscopic Diagnosis
6%
Oncology
6%
Low-grade Dysplasia
6%
Multicenter Cohort Study
6%
Computer-aided Detection (CADe)
6%
Near-infrared
6%
Bevacizumab
6%
Neoplasia
5%
Confidence Interval
5%
Endoscopy
5%